Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D - PubMed (original) (raw)

• PMID: 3009551
• PMCID: PMC424571
• DOI: 10.1172/JCI112483

Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D

S Balsan et al. J Clin Invest. 1986 May.

Abstract

We report the beneficial effects of calcium infusions in a child with hereditary resistance to 1,25(OH)2D and alopecia. This patient after transient responsiveness to vitamin D derivatives became unresponsive to all therapy despite serum 1,25(OH)2D concentrations maintained at levels approximately 100-fold normal. A 7-mo trial with calcium infusions led to correction of biochemical abnormalities and healing of rickets. Bone biopsies (n = 3) showed a normal mineralization and the disappearance of the osteomalacia. Cultures of bone-derived cells demonstrated a lack of activation of 25-hydroxyvitamin D 24-hydroxylase and osteocalcin synthesis by 1,25(OH)2D3 (10(-9) and 10(-6) M). These results demonstrate that even in the absence of a normal 1,25(OH)2D3 receptor-effector system in bone cells, normal mineralization can be achieved in humans if adequate serum calcium and phosphorus concentrations are maintained; and calcium infusions may be an efficient alternative for the management of patients with this condition who are unresponsive to large doses of vitamin D derivatives.

PubMed Disclaimer

Similar articles

• Hereditary resistance to 1,25-dihydroxyvitamin D: clinical and radiological improvement during high-dose oral calcium therapy.
  Sakati N, Woodhouse NJ, Niles N, Harfi H, de Grange DA, Marx S. Sakati N, et al. Horm Res. 1986;24(4):280-7. doi: 10.1159/000180568. Horm Res. 1986. PMID: 3023230
• Rickets and alopecia with resistance to 1,25-dihydroxyvitamin D: two different clinical courses with two different cellular defects.
  Balsan S, Garabedian M, Liberman UA, Eil C, Bourdeau A, Guillozo H, Grimberg R, Le Deunff MJ, Lieberherr M, Guimbaud P, Broyer M, Marx SJ. Balsan S, et al. J Clin Endocrinol Metab. 1983 Oct;57(4):803-11. doi: 10.1210/jcem-57-4-803. J Clin Endocrinol Metab. 1983. PMID: 6309886
• Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol.
  Harrell RM, Lyles KW, Harrelson JM, Friedman NE, Drezner MK. Harrell RM, et al. J Clin Invest. 1985 Jun;75(6):1858-68. doi: 10.1172/JCI111900. J Clin Invest. 1985. PMID: 3839245 Free PMC article.
• The combined use of intravenous and oral calcium for the treatment of vitamin D dependent rickets type II (VDDRII).
  al-Aqeel A, Ozand P, Sobki S, Sewairi W, Marx S. al-Aqeel A, et al. Clin Endocrinol (Oxf). 1993 Aug;39(2):229-37. doi: 10.1111/j.1365-2265.1993.tb01779.x. Clin Endocrinol (Oxf). 1993. PMID: 8396512 Review.
• Hereditary resistance to 1,25-dihydroxyvitamin D.
  Marx SJ, Liberman UA, Eil C, Gamblin GT, DeGrange DA, Balsan S. Marx SJ, et al. Recent Prog Horm Res. 1984;40:589-620. doi: 10.1016/b978-0-12-571140-1.50019-0. Recent Prog Horm Res. 1984. PMID: 6091196 Review. No abstract available.

Cited by

• Hereditary vitamin D resistant rickets (HVDRR) case series: phenotype, genotype, conventional treatment, and adjunctive cinacalcet therapy.
  Ahmad N, Ansari SA, Aleysae NA, Heaphy ELG, Sobaihi MM, Alghamdi BA, Alzahrani AS. Ahmad N, et al. Pediatr Endocrinol Diabetes Metab. 2024;30(2):74-80. doi: 10.5114/pedm.2024.139367. Pediatr Endocrinol Diabetes Metab. 2024. PMID: 39026484 Free PMC article.
• Loss of maternal calcitriol reversibly alters early offspring growth and skeletal development in mice.
  Hartery SA, Kirby BJ, Walker EC, Kaufmann M, Jones G, St-Arnaud R, Sims NA, Kovacs CS. Hartery SA, et al. J Bone Miner Res. 2024 May 24;39(5):595-610. doi: 10.1093/jbmr/zjae035. J Bone Miner Res. 2024. PMID: 38477809 Free PMC article.
• Development of ZnCdSe/ZnS quantum dot-based fluorescence immunochromatographic assay for the rapid visual and quantitative detection 25⁃hydroxyvitamins D in human serum.
  Wang J, Sun G, Li F, Zhu Z, Sun L, Lv P, Yue H. Wang J, et al. Front Bioeng Biotechnol. 2023 Dec 22;11:1326254. doi: 10.3389/fbioe.2023.1326254. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 38188486 Free PMC article.
• Hereditary Metabolic Bone Diseases: A Review of Pathogenesis, Diagnosis and Management.
  Charoenngam N, Nasr A, Shirvani A, Holick MF. Charoenngam N, et al. Genes (Basel). 2022 Oct 17;13(10):1880. doi: 10.3390/genes13101880. Genes (Basel). 2022. PMID: 36292765 Free PMC article. Review.
• Effects of Extracellular Osteoanabolic Agents on the Endogenous Response of Osteoblastic Cells.
  Alloisio G, Ciaccio C, Fasciglione GF, Tarantino U, Marini S, Coletta M, Gioia M. Alloisio G, et al. Cells. 2021 Sep 10;10(9):2383. doi: 10.3390/cells10092383. Cells. 2021. PMID: 34572032 Free PMC article. Review.

References

1. 1. J Clin Invest. 1971 Jan;50(1):21-34 - PubMed
2. 1. J Clin Invest. 1965 Jun;44:942-6 - PubMed
3. 1. Biochemistry. 1974 Mar 26;13(7):1543-8 - PubMed
4. 1. Clin Chim Acta. 1974 Jul 31;54(2):235-42 - PubMed
5. 1. J Nutr. 1976 Sep;106(9):1265-71 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • American Society for Clinical Investigation
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database